Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s74, 2022. DOI: 10.25251/skin.6.supp.74. Disponível em: https://skin.dermsquared.com/skin/article/view/1831. Acesso em: 24 oct. 2025.